2. Immunology/Inflammation Apoptosis Protein Tyrosine Kinase/RTK
  3. TREM receptor TNF Receptor Interleukin Related c-Fms
  4. TREM-1 inhibitory peptide GF9

TREM-1 inhibitory peptide GF9  (Synonyms: Human TREM-1(213-221))

Cat. No.: HY-P10086 Purity: 99.41%
COA
SDS
Handling Instructions Technical Support

TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

TREM-1 inhibitory peptide GF9

TREM-1 inhibitory peptide GF9 Chemical Structure

CAS No. : 1289375-12-7

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

TREM-1 inhibitory peptide GF9 Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE TREM-1 inhibitory peptide GF9

View All TREM receptor Isoform Specific Products:

View All Isoforms
TREM-1 TREM-2

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22 IL-18

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer[1][2].

IC50 & Target[1]

TREM-1

 

IL-1β

 

IL-6

 

TNF-α

 

In Vitro

TREM-1 inhibitory peptide GF9 (incubated for 6 h) colocalizes with TREM-1 on the cell membrane of J774A.1 mouse macrophages[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

TREM-1 inhibitory peptide GF9 Related Antibodies
In Vivo

The TREM-1 inhibitory peptide GF9 (2.5-25 mg/kg; i.p.; once daily for 14 consecutive days) and its HDL-encapsulated variant (equivalent to 2.5-4 mg/kg of GF9; i.p.; once daily for 14 consecutive days) significantly ameliorate Collagen (HY-NP003)-induced arthritis in DBA/1 mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: DBA/1 (male, 6-7 weeks old, mean weight 20 g, collagen-induced arthritis model)[1]
Dosage: 2.5 mg/kg (free GF9, GF9-dHDL, GF9-sHDL); 25 mg/kg (free GF9); 4 mg/kg GF9 equivalent (GA/E31-dHDL, GA/E31-sHDL)
Administration: i.p.; daily; 14 days
Result: Reduced mean clinical arthritis score to 0.21 on day 38 (25 mg/kg free GF9).
Showed no therapeutic activity at 2.5 mg/kg free GF9.
Achieved therapeutic efficacy comparable to 25 mg/kg free GF9 at 2.5 mg/kg GF9-dHDL and GF9-sHDL.
Reduced clinical arthritis severity at 4 mg/kg GF9 equivalent GA/E31-dHDL and GA/E31-sHDL, with GA/E31-sHDL efficacy comparable to 25 mg/kg free GF9.
Reduced summed histopathology scores by 96% vs. vehicle and 97% vs.
GF9-G (25 mg/kg free GF9).
Reduced inflammation by 94%, pannus formation by 98%, cartilage damage by 96%, bone resorption by 99%, and periosteal bone formation by 98% (25 mg/kg free GF9 vs.
GF9-G).
Reduced histopathology scores by 66-88% vs. vehicle/GF9-G (GF9-dHDL, GF9-sHDL, GA/E31-dHDL, GA/E31-sHDL).
Increased body weight gain to levels comparable to non-arthritic naive mice (all GF9-containing formulations).
Significantly reduced plasma levels of TNFα, IL-1β, IL-6, and M-CSF on days 30 and 38 (25 mg/kg free GF9, 2.5 mg/kg GF9-sHDL, 4 mg/kg GF9 equivalent GA/E31-sHDL).
Molecular Weight

997.19

Formula

C49H76N10O12
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Gly-Phe-Leu-Ser-Lys-Ser-Leu-Val-Phe
Sequence Shortening

GFLSKSLVF
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 1.92 mg/mL (1.93 mM; ultrasonic and adjust pH to 7 with CH3COOH; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.0028 mL 5.0141 mL 10.0282 mL
5 mM --- --- ---
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.0028 mL 5.0141 mL 10.0282 mL 25.0704 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

TREM-1 inhibitory peptide GF9 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

TREM-1 inhibitory peptide GF91289375-12-7Human TREM-1(213-221)TREM receptorTNF ReceptorInterleukin Relatedc-FmsTriggering receptors expressed on myeloid cellsTumor Necrosis Factor ReceptorTNFRILCSF-1 receptorcolony stimulating factor 1 receptorCSF-1RCSF1RDBA/1 miceTriggering receptor expressed on myeloid cells 1pro-inflammatory cytokinesmacrophage colony-stimulating factorcollagen-induced arthritisJ774A.1 murine macrophagesSignaling Chain HOmoOLigomerization modelpancreatic cancerTREM-1DAP-12Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
TREM-1 inhibitory peptide GF9
Cat. No.:
HY-P10086
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.